Penumbra (NYSE:PEN) Cut to “Hold” at Leerink Partnrs

Leerink Partnrs downgraded shares of Penumbra (NYSE:PEN) from a strong-buy rating to a hold rating in a report published on Thursday,Zacks.com reports.

PEN has been the subject of a number of other research reports. BTIG Research lowered shares of Penumbra from a “buy” rating to a “neutral” rating and set a $349.00 target price for the company. in a research report on Thursday. Bank of America boosted their price objective on Penumbra from $320.00 to $370.00 and gave the stock a “buy” rating in a research report on Monday, January 5th. Canaccord Genuity Group raised their target price on Penumbra from $355.00 to $359.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. Wells Fargo & Company reaffirmed an “equal weight” rating and issued a $374.00 price target on shares of Penumbra in a research report on Thursday. Finally, Needham & Company LLC lowered shares of Penumbra from a “buy” rating to a “hold” rating in a research report on Friday. Seven analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $355.88.

Penumbra Stock Up 0.1%

Shares of PEN stock opened at $350.93 on Thursday. The stock’s 50 day simple moving average is $303.54 and its 200 day simple moving average is $269.65. Penumbra has a twelve month low of $221.26 and a twelve month high of $352.15. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.18 and a current ratio of 6.73. The company has a market capitalization of $13.74 billion, a price-to-earnings ratio of 83.95, a PEG ratio of 2.14 and a beta of 0.71.

Penumbra (NYSE:PEN) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.90 by $0.07. Penumbra had a return on equity of 11.35% and a net margin of 12.30%.The company had revenue of $354.69 million for the quarter, compared to the consensus estimate of $340.77 million. During the same quarter last year, the company posted $0.85 earnings per share. The company’s revenue for the quarter was up 17.8% compared to the same quarter last year. As a group, research analysts predict that Penumbra will post 3.67 EPS for the current year.

Insider Transactions at Penumbra

In other news, Director Thomas Wilder sold 186 shares of Penumbra stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $310.72, for a total transaction of $57,793.92. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Arani Bose sold 15,000 shares of the company’s stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $308.82, for a total transaction of $4,632,300.00. Following the completion of the sale, the director directly owned 258,462 shares in the company, valued at approximately $79,818,234.84. The trade was a 5.49% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 34,144 shares of company stock valued at $10,260,127 in the last ninety days. 4.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Penumbra

A number of institutional investors have recently added to or reduced their stakes in the stock. Invesco Ltd. raised its holdings in shares of Penumbra by 1,139.3% in the 2nd quarter. Invesco Ltd. now owns 633,485 shares of the company’s stock worth $162,571,000 after buying an additional 582,369 shares in the last quarter. Norges Bank bought a new stake in Penumbra in the second quarter valued at $114,014,000. Holocene Advisors LP acquired a new position in Penumbra during the third quarter worth $78,585,000. Qube Research & Technologies Ltd bought a new position in shares of Penumbra during the second quarter valued at $53,818,000. Finally, Man Group plc lifted its holdings in shares of Penumbra by 1,862.2% during the second quarter. Man Group plc now owns 206,461 shares of the company’s stock valued at $52,984,000 after acquiring an additional 195,939 shares during the period. 88.88% of the stock is owned by institutional investors and hedge funds.

Key Penumbra News

Here are the key news stories impacting Penumbra this week:

• Positive Sentiment: Boston Scientific agreed to acquire Penumbra for $374 per share in a cash-and-stock deal, citing strategic expansion into mechanical thrombectomy and neurovascular markets — the transaction creates a significant takeover premium that lifted investor interest. Boston Scientific announces agreement to acquire Penumbra, Inc.
• Positive Sentiment: Penumbra issued preliminary Q4 and FY2025 results/guidance showing higher-than-consensus Q4 revenue guidance (~$383.0M–$384.8M vs. $361.9M consensus) and FY revenue around $1.4B — these operational beats support the deal valuation and the company’s growth profile. Penumbra provides preliminary update on Q4 and FY2025 results
• Neutral Sentiment: Wells Fargo cut its rating to Equal Weight but left a $374 price target — the target essentially aligns with the deal price, implying limited upside beyond the acquisition terms unless a competing bid emerges. Penumbra downgraded at Wells Fargo
• Neutral Sentiment: Market commentary and earnings-estimate revisions note strong recent volume and a large one-day surge; analysts point to momentum but caution on sustainability absent competing bids or further fundamentals. Zacks coverage of Penumbra price move
• Negative Sentiment: Needham downgraded Penumbra from Buy to Hold — a straightforward analyst reaction that could weigh on sentiment and aftermarket buying absent a higher competing bid. Penumbra downgraded at Needham
• Negative Sentiment: Multiple shareholder law firms (Kahn Swick & Foti, Halper Sadeh, Ademi, Brodsky & Smith, others) have opened investigations and class-action alerts alleging the sale price/process may be unfair — litigation or legal challenges could delay the deal, lead to renegotiation, or increase transaction costs. Kahn Swick & Foti investor alert on Penumbra sale

About Penumbra

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.